32 Stocks Moving In Tuesday's Mid-Day Session

Gainers

• SemiLEDs Corporation (NASDAQ:LEDS) shares rose 35.8 percent to $4.55.
• EVINE Live Inc. (NASDAQ:EVLV) gained 28.8 percent to $1.04. The pay-TV home shopping company was named as a potential acquisition target by TechCrunch. According to the publication, Amazon.com, Inc. (NASDAQ:AMZN) is exploring ways of marketing its products and services to consumers beyond the internet.
• Sanmina Corp (NASDAQ:SANM) shares surged 19.1 percent to $33.00 as the company reported stronger-than-expected earnings for its second quarter on Monday.
• Heidrick & Struggles International, Inc. (NASDAQ:HSII) gained 14.9 percent to $37.22 as the company posted upbeat results for its first quarter.
• Santander Consumer USA Holdings Inc. (NYSE:SC) shares climbed 14 percent to $17.90 following upbeat quarterly earnings.
• Helix Energy Solutions Group, Inc. (NYSE:HLX) climbed 14 percent to $7.12 following strong quarterly results.
• Check-Cap Ltd. (NASDAQ:CHEK) gained 13.6 percent to $8.25.
• Atossa Genetics Inc. (NASDAQ:ATOS) rose 11.8 percent to $3.34. Atossa Genetics disclosed that it has Received positive interim review from the Independent Safety Committee in Phase 1 Topical endoxifen dose escalation study in men.
• Cadence Design Systems, Inc. (NASDAQ:CDNS) gained 11.6 percent to $40.99 after the company posted upbeat Q1 results and issued a strong Q2 forecast.
• Genprex, Inc. (NASDAQ:GNPX) climbed 11.2 percent to $4.9363.
• Mitel Networks Corporation (NASDAQ:MITL) rose 10.5 percent to $11.23 after the company agreed to be acquired by affiliates of Searchlight Capital Partners for $2.0 billion.
• Systemax Inc. (NYSE:SYX) rose 10.2 percent to $30.86. Sidoti & Co. upgraded Systemax from Neutral to Buy.
• Orchids Paper Products Company (NYSE:TIS) surged 9.2 percent to $7.13. Orchids Paper Products is expected to report its Q1 financial results on Wednesday, April 25, 2018.
• New Oriental Education & Technology Group Inc. (NYSE:EDU) rose 8.1 percent to $93.86 after reporting Q3 results.
• Weatherford International plc (NYSE:WFT) gained 7.3 percent to $2.78 after the company reported a narrower-than-expected quarterly loss.
• Riot Blockchain, Inc. (NASDAQ:RIOT) shares rose 5.4 percent to $6.90 after declining 1.50 percent on Monday.
• SAP SE (NYSE:SAP) rose 4.3 percent to $110.52 after the company posted strong quarterly results and raised its outlook for the year.
• Caterpillar Inc. (NYSE:CAT) rose 3.6 percent to $159.4604 following better-than-expected quarterly results.

Check out these big penny stock gainers and losers

Losers

• Valeritas Holdings Inc (NASDAQ:VLRX) tumbled 29 percent to $1.81. Valeritas priced its 13.7 million share offering at $1.75 per share.
• Stepan Company (NYSE:SCL) dropped 14.5 percent to $76.29 as the company posted downbeat Q1 results.
• Casa Systems, Inc. (NASDAQ:CASA) fell 14 percent to $25.64 after announcing a 7.35 million share common stock offering.
• Epizyme, Inc. (NASDAQ:EPZM) declined 12.6 percent to $13.37. Epizyme announced Monday after the close that the FDA issued a partial clinical hold on the U.S. enrollment of new patients in tazemetostat clinical trials.
• Arcadia Biosciences, Inc. (NASDAQ:RKDA) shares fell 12.1 percent to $17.45.
• BioXcel Therapeutics, Inc. (NASDAQ:BTAI) shares dropped 11.5 percent to $8.00.
• Foresight Autonomous Holdings Ltd (NASDAQ:FRSX) shares declined 10.5 percent to $3.23.
• Waters Corporation (NYSE:WAT) dipped 8.6 percent to $191.51 following Q1 results.
• Inspired Entertainment, Inc. (NASDAQ:INSE) dropped 8.6 percent to $4.80.
• VirnetX Holding Corp (NYSE:VHC) shares declined 7.6 percent to $2.73.
• Erin Energy Corporation (NYSE:ERN) shares slipped 7.6 percent to $2.495.
• 3M Company (NYSE:MMM) dropped 7.4 percent to $200.03 after reporting Q1 results.
• Zealand Pharma A/S (NASDAQ:ZEAL) fell 6.9 percent to $15.24 after rising 9.80 percent on Monday.
• Incyte Corporation (NASDAQ:INCY) fell 6.1 percent to $64.00. Lilly and Incyte disclosed that the FDA Advisory Committee recommended approval of baricitinib 2mg, but not 4mg, for the treatment of moderately-to-severely active RAI.